Short Term Oral Zinc Supplementation among Babies with Neonatal Sepsis for Reducing Mortality and Improving Outcome - A Double-Blind Randomized Controlled Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

PubMed tags the participants as both men and women.

The no zinc group was on antibiotic treatment.

The babies were followed up till 12 mo corrected age using DASII (Development Assessment Scale for Indian Infants).

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The clinical trial was undertaken in the neonatal intensive care unit of JIPMER during the time period from September 2013 through December 2016.

Neonates with clinical manifestations of sepsis who exhibited two positive screening tests (microESR, C- reactive protein, band cell count) were included and randomized into no zinc and zinc group.

Blood samples from both groups were collected at baseline and after day 10.

Babies were carefully discharged from the hospital.

What Was Measured

Topics PubMed links to this paper include Neonatal Sepsis and Zinc Sulfate.

The authors tagged it with the keywords Mortality, Neurodevelopment and Outcome.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Indian journal of pediatrics), a journal based in India.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.